ClinicalTrials.gg
Active, not recruitingNCT06921356DASH-LifeUpdated Nov 17, 2026

Groceries Plus Multi-Component Lifestyle Intervention for Adults With Hypertension and Type 2 Diabetes

An interventional study of Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention and Self-Shopping DASH diet advice in Hypertension and Type 2 Diabetes Mellitus (T2DM), sponsored by Johns Hopkins University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Other

How we know

Updated Nov 17, 2026Now Active, not recruitingEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 50 studies in Hypertension by Johns Hopkins University — 10 open to participants now, 14 under way, none of them phase 3. Hypertension · Johns Hopkins University.

Enrollment
34th of 44
81 · median 138
Started
2025
with 1 other
No phase
39 of 50
6 open now
Primary completion
2027-03
later than 3 of 13 live
Registered
41st of 50
by date

Among the 50 studies in Hypertension by Johns Hopkins University, this one is the 34th largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2025, is one of 39 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 41st registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

10 of the 50 studies in Hypertension by Johns Hopkins University are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hypertension by Johns Hopkins University, or all of them as a file.
02

Study summary

People with high blood pressure and diabetes often have low levels of key nutrients as a result of not eating enough fresh fruits and vegetables. Research studies suggest that these nutrients can lower blood pressure and blood sugar. This study will investigate if providing encouragement to adopt this healthy and nutritious way of eating and providing guidance on weight management will lower blood pressure and blood sugar. The DASH-Life research study will recruit adults with hypertension and type 2 diabetes who live in Baltimore metro areas that don't have many stores selling healthy foods. The DASH-Life research study is 6 months long. Participants will be randomly assigned to one of two groups: 1) Self-Shopping DASH (S-DASH) diet advice group, or 2) Coaching DASH (C-DASH) diet advice group.

03

Conditions studied

  • Hypertension
  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • hypertension
  • type 2 diabetes
  • diet
04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diabetes Mellitus Type 2 defined by: self-reported type 2 diabetes diagnosis, or >=6.5%, or treatment of diabetes with diabetes medications(s)
  • Baseline systolic BP 110-159 mmHg (with or without medications.)
  • Serum potassium level >3.0 and \<5 mmol/L,
  • Estimated (eGFR) >=45 mL/min/1.73m2.
  • Willing and able to complete required procedures in English.
  • Living in Healthy Food Priority Area in Baltimore; the US Department of Agriculture (USDA) defined low income, low access areas, or census blocks with area deprivation index (ADI) 60 and above (State Decile>=6.)

Exclusion criteria

Exclusion Criteria:

  • Hypoglycemia requiring hospitalization or the assistance of another person in the last 6 months
  • Cardiovascular event within 6 months
  • Unstable dose (i.e., change in the 3 months prior to screening or prior to randomization) glucagon-like peptide-1 (GLP-1) receptor agonists
  • ≥ 10%
  • Type 1 diabetes
  • Baseline systolic BP \< 110 mmHg
  • Weight >400 lbs due to the maximum weight on study scale
  • Chronic disease that might interfere with trial participation
  • Current participation in another clinical trial that might affect blood pressure, weight loss, diabetes, or ability to adhere to study procedures
  • Current participation in program with conflicting dietary guidance (i.e., meal replacement or keto diets)
  • Unwillingness or inability to adopt a DASH-like diet
  • Planning to leave area in the next 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    Self-Shopping DASH diet advice group (S-DASH)

    Behavioral: Self-Shopping DASH diet advice

  • Experimental
    Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention (C-DASH)

    Behavioral: Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention

Interventions

  • BehavioralCoach-Directed Tailored DASH Groceries Plus Lifestyle Intervention

    Participants assigned to the C-DASH group will meet by telephone with the study coach for 1 hour, and then have brief weekly conversations (about 15-30 minutes) by phone during the first three months. During these weekly calls, the study coach will assist participant with selecting fruits, vegetables, nuts, and beans. During months 4-6, the study coach will continue to work with participant to set goals for following the DASH-Life way of eating, but the study will no longer provide a weekly food allowance to purchase groceries.

  • BehavioralSelf-Shopping DASH diet advice

    Participants assigned to the S-DASH group will receive a brochure about the DASH eating plan. For the first three months, Participants will also receive a gift card to shop at a local supermarket. During months 4-6, participants will be asked to continue following the DASH eating plan listed in the brochure but will no longer be provided the grocery gift card.

06

What researchers measure

Primary outcomes

  1. Feasibility as assessed by the number of participants enrolled

    The observed count of responses to the prescreening will be summarized. Recruitment yields at screening visit and randomization visit will be derived.

    Time frame: Baseline

  2. Acceptability as assessed by the Acceptability of the Intervention Measure survey

    Acceptability of the intervention will be quantitatively measured by the Acceptability of Intervention Measure (AIM) survey. The survey consists of 4 items, each measured on a 5-point Likert scale from 1 (completely disagree) to 5 (completely agree). The score is calculated as the mean of the responses to the 4 items. A higher score is better.

    Time frame: 3 months

07

Study locations

1 site
  • Johns Hopkins ProHealth Clinical Research Unit
    Baltimore, Maryland 21207, United States
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 10, 2025
StartActual
May 15, 2025
Primary completionEst.
Mar 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 5, 2026
Enrollment
80 (estimated)→81 (actual)
Nov 17, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedBaseline systolic BP 120110-159 mmHg (with or without medications.)
Exclusion criteria
  • RemovedOn diabetes or weight loss medications such as glucagon-like peptide 1 (GLP-1), GLP-1/glucose-dependent insulin-releasing peptide (GIP), insulin, or any combination of these medications
  • AddedUnstable dose (i.e., change in the 3 months prior to screening or prior to randomization) glucagon-like peptide-1 (GLP-1) receptor agonists
  • EditedBaseline systolic BP < 100110 mmHg
Nov 5, 2026
Show all 2 updates
  1. Nov 17, 2026
    Enrollment 80 (estimated)→81 (actual)
  2. Nov 5, 2026
    Recruiting→Active, not recruiting
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedBaseline systolic BP 120110-159 mmHg (with or without medications.)
    Exclusion criteria
    • RemovedOn diabetes or weight loss medications such as glucagon-like peptide 1 (GLP-1), GLP-1/glucose-dependent insulin-releasing peptide (GIP), insulin, or any combination of these medications
    • AddedUnstable dose (i.e., change in the 3 months prior to screening or prior to randomization) glucagon-like peptide-1 (GLP-1) receptor agonists
    • EditedBaseline systolic BP < 100110 mmHg
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06921356
Responsible party
Sponsor
First posted
Apr 10, 2025
Start date
May 15, 2025
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Jessica Yeh, PhD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion